Eliot Bourk
Corporate Officer/Principal chez CHIMERIC THERAPEUTICS LIMITED
Fortune : 82 412 $ au 30/04/2024
Profil
Eliot Bourk is currently the Chief Business Officer & Head-External Innovation at Chimeric Therapeutics Ltd.
(Australia).
Previously, he worked at Celgene Corp.
as a Member.
He holds a doctorate degree from the University of California.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 4 230 603 ( 0,50% ) | 82 412 $ | 30/04/2024 |
Postes actifs de Eliot Bourk
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Corporate Officer/Principal | 23/02/2021 |
Anciens postes connus de Eliot Bourk
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
Formation de Eliot Bourk
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |